Emerging Markets Earnings Roundup: Novartis (Part 3)
This article was originally published in PharmAsia News
Novartis had a busy second quarter with Diovan in the news and a major deal with GSK that portends an evolving focus in emerging markets.
You may also be interested in...
Novartis announced Vas Narasimhan will be global head of development for Novartis’ pharma unit, and Rainer Boehm will be chief commercial officer of general medicines.
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.